GSK233705
Sponsors
GlaxoSmithKline
Conditions
Pulmonary Disease, Chronic Obstructive
Phase 1
Safety Study Using GSK233705 And Tiotropium In Patients With Chronic Obstructive Pulmonary Disease
CompletedNCT00279019
Start: 2005-12-12End: 2006-06-13Updated: 2017-09-25
A Single Centre Randomized Study Evaluating The Safety And Tolerability Of GSK233705 In Healthy Volunteers.
CompletedNCT00453687
Start: 2007-03-09End: 2007-05-16Updated: 2017-08-07
Study To Examine Safety, Tolerability And Pharmacokinetics Of Intravenous Doses And Oral Dose Of GSK233705
CompletedNCT00500461
Start: 2007-06-04End: 2007-07-25Updated: 2017-08-07
A Study to Assess the Safety and Pharmacokinetics of Inhaled Doses of GSK233705 and GW642444 in Healthy Subjects.
CompletedNCT00671216
Start: 2008-05-20End: 2008-07-07Updated: 2017-10-04
A Study to Assess the Safety and Pharmacokinetics of Inhaled Doses of GSK233705 and GW642444 in Healthy Subjects
CompletedNCT00783003
Start: 2008-11-10End: 2009-02-06Updated: 2017-07-18
Phase I Study of GSK233705 in Healthy Japanese Male Subjects
CompletedNCT00964405
Start: 2008-09-20End: 2008-12-20Updated: 2017-08-03
Phase 2
Safety And Tolerability Study In Patients With Chronic Obstructive Pulmonary Disease
CompletedNCT00376714
Start: 2006-08-16End: 2007-04-03Target: 45Updated: 2018-06-07
Safety And Efficacy Of GSK233705 Plus Salmeterol Compared With 2 Active Comparators And Placebo In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
CompletedNCT00422604
Start: 2006-10-31End: 2007-05-31Updated: 2016-10-28